The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced […]readmore
Tags : Revlimid
Shots: The approval is based on P-III AUGUMENT study involves assessing of Revlimid + Rituximab (R2) vs rituximab +PBO in patients with previously treated follicular lymphoma (FL) or marginal zone […]readmore
Shots: The approval is based on P-III AUGMENT study results assessing Revlimid + Rituximab (R2) vs rituximab + PBO in patients with previously treated FL & MZL, following its PR […]readmore